Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ProMIS Neurosciences Inc.PMN · Entity 6643 | Director | April 22, 2026 | April 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ProMIS Neurosciences Inc.
Report date April 22, 2026 · Filed April 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectBy Patrick D. Kirwin Professional Corp | 4,653 |
Reported balance
After 2026-04-22 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-04-22 · Purchase · Acquired 4,000 · Balance 4,653 |
| Common SharesSEC Table I · non-derivative | IndirectBy his spouse | 305 |
Reported balance
Holding disclosure · report date 2026-04-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 305 |
| Common SharesSEC Table I · non-derivative | Direct | 5,135 |
Reported balance
Holding disclosure · report date 2026-04-22 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,135 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 22, 2026 Filed Apr 24, 2026 01:25 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseCommon Shares | 4,000 | $11.33 | $45,320.00 |
DisclosureSEC source: 0001104659-26-047977 · tm2612640-1_4seq1.xml · nonDerivative · entry 1 Kirwin Patrick D. · CIK 0001927062 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Patrick D. Kirwin Professional Corp Disclosed balance after: 4,653 Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 01:36 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantWarrants to purchase Common Shares · Derivative | 3,050 | Not disclosed Strike: $14.40 | Not disclosed |
DisclosureSEC source: 0001104659-26-011135 · tm265402d1_4seq1.xml · derivative · entry 4 Kirwin Patrick D. · CIK 0001927062 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,050 Underlying: Common Shares · 3,050 shares Expires 2031-02-03 F1 · kind: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant. F1 · price: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant. F3 · derivative.expiration_date: The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 01:36 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantCommon Shares | 3,050 | $12.13 | $36,996.50 |
DisclosureSEC source: 0001104659-26-011135 · tm265402d1_4seq1.xml · nonDerivative · entry 1 Kirwin Patrick D. · CIK 0001927062 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,135 F1 · kind: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant. F1 · price: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant. F2 · balance_after: Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 21:11 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001374339-25-000005 · primary_doc.xml · derivative · entry 1 Kirwin Patrick D. · CIK 0001927062 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The options shall vest in full on the earlier of the first anniversary of the Grant Date and June 12, 2026, subject to continued service on the Board. Read SEC document |
| October 03, 2024 Filed Oct 7, 2024 22:36 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-24-106766 · tm2425760-1_4seq1.xml · derivative · entry 1 Kirwin Patrick D. · CIK 0001927062 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2034-10-03 F1 · derivative.exercise_date: 33% of the shares subject to this option vested on October 3, 2024, and the balance shall vest ratably over the following 24 months, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 11:38 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseCommon Shares | 10,000 | $1.25 | $12,492.00 |
DisclosureSEC source: 0001374339-24-000002 · primary_doc.xml · nonDerivative · entry 1 Kirwin Patrick D. · CIK 0001927062 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,983 Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantWarrants to purchase Common Shares · Derivative | 11,000 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0000899243-23-018460 · doc4.xml · derivative · entry 5 Kirwin Patrick D. · CIK 0001927062 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Shares · 11,000 shares Expires 2029-02-21 F1 · kind: On August 23, 2023, pursuant to a Unit Purchase Agreement entered into by the Company with selected investors (the "Offering"), the Reporting Person acquired 11,000 common share units (each, a "Common Share Unit"), each unit consisting of one of the Company's common shares, no par value (the "Common Shares"), and one warrant to purchase one Common Share. The purchase price for each Common Share Unit was $1.88 per Common Share Unit. F1 · price: On August 23, 2023, pursuant to a Unit Purchase Agreement entered into by the Company with selected investors (the "Offering"), the Reporting Person acquired 11,000 common share units (each, a "Common Share Unit"), each unit consisting of one of the Company's common shares, no par value (the "Common Shares"), and one warrant to purchase one Common Share. The purchase price for each Common Share Unit was $1.88 per Common Share Unit. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantCommon Shares | 11,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-018460 · doc4.xml · nonDerivative · entry 1 Kirwin Patrick D. · CIK 0001927062 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,983 F1 · kind: On August 23, 2023, pursuant to a Unit Purchase Agreement entered into by the Company with selected investors (the "Offering"), the Reporting Person acquired 11,000 common share units (each, a "Common Share Unit"), each unit consisting of one of the Company's common shares, no par value (the "Common Shares"), and one warrant to purchase one Common Share. The purchase price for each Common Share Unit was $1.88 per Common Share Unit. F1 · price: On August 23, 2023, pursuant to a Unit Purchase Agreement entered into by the Company with selected investors (the "Offering"), the Reporting Person acquired 11,000 common share units (each, a "Common Share Unit"), each unit consisting of one of the Company's common shares, no par value (the "Common Shares"), and one warrant to purchase one Common Share. The purchase price for each Common Share Unit was $1.88 per Common Share Unit. Read SEC document |
| December 15, 2022 Filed Dec 15, 2022 23:05 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseCommon Shares | 2,000 | $4.51 | $9,020.00 |
DisclosureSEC source: 0001927062-22-000002 · primary_doc.xml · nonDerivative · entry 2 Kirwin Patrick D. · CIK 0001927062 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Patrick D. Kirwin Professional Corp Disclosed balance after: 27,998 F2 · price: The purchase price of CAD$6.16 has been converted to USD based on the WSJ exchange rate on December 15, 2022 of CAD$1.00=US$0.7322 Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 23:05 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseCommon Shares | 1,000 | $4.87 | $4,870.00 |
DisclosureSEC source: 0001927062-22-000002 · primary_doc.xml · nonDerivative · entry 1 Kirwin Patrick D. · CIK 0001927062 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Patrick D. Kirwin Professional Corp Disclosed balance after: 25,998 F1 · price: The purchase price of CAD$6.60 has been converted to USD based on the WSJ exchange rate on December 13, 2022 of CAD$1.00=US$0.7383 Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 16:43 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseCommon Shares | 1,000 | $4.98 | $4,980.00 |
DisclosureSEC source: 0001927062-22-000001 · primary_doc.xml · nonDerivative · entry 1 Kirwin Patrick D. · CIK 0001927062 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Patrick D. Kirwin Professional Corp Disclosed balance after: 24,998 F1 · price: The purchase price of CAD$6.80 has been converted to USD based on the WSJ exchange rate on December 9, 2022 of CAD$1.00=US$0.7329 Read SEC document |
| August 17, 2022 Filed Aug 18, 2022 20:05 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseCommon Shares | 4,000 | $5.92 | $23,680.00 |
DisclosureSEC source: 0001062993-22-018369 · form4.xml · nonDerivative · entry 1 Kirwin Patrick D. · CIK 0001927062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,983 F1 · price: The purchase price of CAD$7.65 has been converted to USD based on the Bank of Canada exchange rate on August 17, 2022 of CAD$1.2912= US$1.00. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.